Oral calcium salts are recommended for the treatment of chronic hypoparathyroidism (HypoPT), although dosimetry is variable between individual patients and clinicians. However, patient feedback on calcium salts can be negative, particularly due to gastrointestinal side effects and hypercalciuria-related complications. We begin with a clinical case of a HypoPT patient taking oral calcium salts following thyroid surgery, who requested support in reducing her dose of these with a view to stopping entirely. To evaluate her request, we first describe the usual treatment of HypoPT according to current guidance and then present data from (a) a case note review of a cohort of 24 HypoPT patients managed with a "no calcium" treatment regimen by single physician (b) a comprehensive online survey of HypoPT patients' treatment and experiences (n = 330). The case note review found that target range serum calcium levels were successfully achieved in all 24 patients since transitioning to a "no calcium" regimen, without any breakthrough hypocalcaemia-related symptoms, the development of new renal stones, the occurrence of calcium-related hospital admissions or the finding of significant hypercalciuria. The online survey identified 36% of HypoPT patients who continued to take activated vitamin D, but had discontinued calcium supplements. HypoPT patients not currently taking calcium reported a significantly lower prevalence of adverse effects and outcomes, both compared with their previous experiences whilst taking calcium and also compared with the 64% of patients who continued to take oral calcium. We conclude that, subject to methodological limitations, there are significant issues of tolerability arising from conventional calcium-based treatment regimens for patients with chronic HypoPT. For selected patients, it may be reasonable to facilitate a managed therapeutic transition to "no calcium" regimen, and we also propose that calcium-based regimes be prospectively evaluated against calcium-free (or calcium-low) alternatives.
Keywords: Calcium; Hypoparathyroidism; dyspepsia; hospitalization; patient survey; vitamin D.
© 2019 John Wiley & Sons Ltd.
Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study.J Bone Miner Res. 2013 Nov;28(11):2277-85. doi: 10.1002/jbmr.1979. J Bone Miner Res. 2013. PMID: 23661265
Endocrine Complications of Surgical Treatment of Thyroid Cancer: An Update.Exp Clin Endocrinol Diabetes. 2017 Sep;125(8):497-505. doi: 10.1055/s-0043-106441. Epub 2017 Apr 25. Exp Clin Endocrinol Diabetes. 2017. PMID: 28444664 Review.
American Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis, Prevention, and Management in Adults.Thyroid. 2018 Jul;28(7):830-841. doi: 10.1089/thy.2017.0309. Epub 2018 Jun 29. Thyroid. 2018. PMID: 29848235
Bone Status Among Patients With Nonsurgical Hypoparathyroidism, Autosomal Dominant Hypocalcaemia, and Pseudohypoparathyroidism: A Cohort Study.J Bone Miner Res. 2018 Mar;33(3):467-477. doi: 10.1002/jbmr.3328. Epub 2017 Nov 30. J Bone Miner Res. 2018. PMID: 29087612
Hypoparathyroidism: Replacement Therapy with Parathyroid Hormone.Endocrinol Metab (Seoul). 2015 Dec;30(4):436-42. doi: 10.3803/EnM.2015.30.4.436. Epub 2015 Sep 22. Endocrinol Metab (Seoul). 2015. PMID: 26394728 Free PMC article. Review.
Cited by 2 articles
Burden of illness in not adequately controlled chronic hypoparathyroidism: Findings from a 13-country patient and caregiver survey.Clin Endocrinol (Oxf). 2020 Feb;92(2):159-168. doi: 10.1111/cen.14128. Epub 2019 Dec 11. Clin Endocrinol (Oxf). 2020. PMID: 31721256 Free PMC article.
Defining the Characteristics of Chronic Hypoparathyroidism Not Adequately Controlled on Conventional Therapy: Consensus Findings of Three European Delphi Panels.Adv Ther. 2019 Nov;36(11):3007-3016. doi: 10.1007/s12325-019-01102-5. Epub 2019 Oct 5. Adv Ther. 2019. PMID: 31587144 Free PMC article.